251 related articles for article (PubMed ID: 14633783)
21. Experience with ruxolitinib in the treatment of polycythaemia vera.
Alimam S; Harrison C
Ther Adv Hematol; 2017 Apr; 8(4):139-151. PubMed ID: 28491265
[TBL] [Abstract][Full Text] [Related]
22. Contemporary Challenges in Polycythemia Vera Management From the Perspective of Patients and Physicians.
Kuykendall AT; Fine JT; Kremyanskaya M
Clin Lymphoma Myeloma Leuk; 2024 Apr; ():. PubMed ID: 38749802
[TBL] [Abstract][Full Text] [Related]
23. Polycythemia vera: past, present and future.
Patel AB; Masarova L; Mesa RA; Hobbs G; Pemmaraju N
Leuk Lymphoma; 2024 Jun; ():1-13. PubMed ID: 38871488
[TBL] [Abstract][Full Text] [Related]
24. Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL.
Gerds AT; Mesa R; Burke JM; Grunwald MR; Stein BL; Squier P; Yu J; Hamer-Maansson JE; Oh ST
Blood; 2024 Apr; 143(16):1646-1655. PubMed ID: 38142448
[TBL] [Abstract][Full Text] [Related]
25. Analysis of real-world data demonstrating the efficacy of current management of polycythaemia vera in attaining and maintaining therapeutic haematocrit.
Buckley FD; Arnold C; Brass D; Catherwood M; McMullin MF
Ir J Med Sci; 2024 Apr; 193(2):833-836. PubMed ID: 37682452
[TBL] [Abstract][Full Text] [Related]
26. Antithrombotic Management in Ischemic Stroke with Essential Thrombocythemia: Current Evidence and Dilemmas.
Das S; Deb A; Pal T
Med Princ Pract; 2021; 30(5):412-421. PubMed ID: 33849034
[TBL] [Abstract][Full Text] [Related]
27. Polycythemia vera and essential thrombocythemia of intermediate-age: A real-life, multicenter analysis of first-line treatment approach.
Sobieralski P; Bieniaszewska M; Bołkun Ł; Sacha T; Muzalewska-Wolska M; Homenda W; Bartkowiak ŁK; Smith J; Rymko M; Jachalska A; Mital AR; Prejzner W; Zaucha J
Adv Clin Exp Med; 2024 Apr; ():. PubMed ID: 38683044
[TBL] [Abstract][Full Text] [Related]
28. Advances and challenges in the management of essential thrombocythemia.
Birgegård G
Ther Adv Hematol; 2015 Jun; 6(3):142-56. PubMed ID: 26137205
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.
Vannucchi AM; Guglielmelli P; Rambaldi A; Bogani C; Barbui T
J Cell Mol Med; 2009 Aug; 13(8A):1437-50. PubMed ID: 19522842
[TBL] [Abstract][Full Text] [Related]
30. Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice.
Chojecki A; Boselli D; Dortilus A; Hamadeh I; Begley S; Chen T; Bose R; Podoltsev N; Zeidan AM; Balmaceda NB; Yacoub A; Ai J; Knight TG; Ragon BK; Shah NA; Sanikommu SR; Symanowski J; Mesa R; Grunwald MR
Ann Hematol; 2024 Apr; ():. PubMed ID: 38662203
[TBL] [Abstract][Full Text] [Related]
31. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Kiladjian JJ; Marin FF; Al-Ali HK; Alvarez-Larrán A; Beggiato E; Bieniaszewska M; Breccia M; Buxhofer-Ausch V; Cerna O; Crisan AM; Danaila CD; De Stefano V; Döhner K; Empson V; Gora-Tybor J; Griesshammer M; Grosicki S; Guglielmelli P; García-Gutierrez V; Heidel FH; Illés A; Tomuleasa C; James C; Koschmieder S; Krauth MT; Krejcy K; Lazaroiu MC; Mayer J; Nagy ZG; Nicolini FE; Palandri F; Pappa V; Reiter AJ; Sacha T; Schlager S; Schmidt S; Terpos E; Unger M; Wölfler A; Cirici BX; Klade C
Ann Hematol; 2024 Mar; ():. PubMed ID: 38438627
[TBL] [Abstract][Full Text] [Related]
32. Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.
Barbui T; Vannucchi AM; De Stefano V; Carobbio A; Ghirardi A; Carioli G; Masciulli A; Rossi E; Ciceri F; Bonifacio M; Iurlo A; Palandri F; Benevolo G; Pane F; Ricco A; Carli G; Caramella M; Rapezzi D; Musolino C; Siragusa S; Rumi E; Patriarca A; Cascavilla N; Mora B; Cacciola E; Mannarelli C; Loscocco GG; Guglielmelli P; Gesullo F; Betti S; Lunghi F; Scaffidi L; Bucelli C; Vianelli N; Bellini M; Finazzi MC; Tognoni G; Rambaldi A
NEJM Evid; 2023 Jun; 2(6):EVIDoa2200335. PubMed ID: 38320126
[TBL] [Abstract][Full Text] [Related]
33. Inflammation as a cause of acute myocardial infarction in patients with myeloproliferative neoplasm.
Tirandi A; Schiavetta E; Maioli E; Montecucco F; Liberale L
World J Cardiol; 2024 Feb; 16(2):58-63. PubMed ID: 38456066
[TBL] [Abstract][Full Text] [Related]
34. The Impact of Mean Platelet Volume (MPV) and JAK-2 Mutation on Thrombosis in Chronic Myeloproliferative Diseases.
Ayer M; Menken İ; Yamak M; Ayer FA; Kırkızlar O; Burak Aktuğlu M
Indian J Hematol Blood Transfus; 2017 Jun; 33(2):181-187. PubMed ID: 28596648
[TBL] [Abstract][Full Text] [Related]
35. Platelet proteo-transcriptomic profiling validates mediators of thrombosis and proteostasis in patients with myeloproliferative neoplasms.
Kelliher S; Gamba S; Weiss L; Shen Z; Marchetti M; Schieppati F; Scaife C; Madden S; Bennett K; Fortune A; Maung S; Fay M; Ní Áinle F; Maguire P; Falanga A; Kevane B; Krishnan A
bioRxiv; 2023 Oct; ():. PubMed ID: 37961700
[TBL] [Abstract][Full Text] [Related]
36. Assessment of Endothelial Dysfunction With Flow-Mediated Dilatation in Myeloproliferative Disorders.
Yildiz A; Güryildirim M; Pepeler MS; Yazol M; Oktar SÖ; Acar K
Clin Appl Thromb Hemost; 2018 Oct; 24(7):1102-1108. PubMed ID: 29683036
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy and safety of peginterferon-α2b for treatment of myeloproliterative neoplasms].
Luo D; Luo J; Liang H; He Z; Chen H; Wen Z; Wang Q; Zhou X; Liu X; Xu N
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jun; 43(6):1029-1034. PubMed ID: 37439177
[TBL] [Abstract][Full Text] [Related]
38. Severe thrombocytosis and anemia associated with celiac disease in a young female patient: a case report.
Voigt W; Jordan K; Sippel C; Amoury M; Schmoll HJ; Wolf HH
J Med Case Rep; 2008 Apr; 2():96. PubMed ID: 18380894
[TBL] [Abstract][Full Text] [Related]
39. Retinal Vessel Analysis and Microvascular Abnormalities in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms.
Roszkowska AM; Leanza R; Aragona E; Gargiulo L; Alibrandi A; Arrigo A; Bottaro A; Barone P; Stagno F; Allegra A
J Clin Med; 2024 Apr; 13(8):. PubMed ID: 38673505
[No Abstract] [Full Text] [Related]
40. How I Treat Low-risk Polycythemia Vera Patients who Require Cytoreduction.
McMullin MF; Harrison CN
Blood; 2024 Jun; ():. PubMed ID: 38848538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
